Male Infertility. Oligospermia
Conditions
Interventions
Intervention 1: Intervention group: Oligoasthenoteratozoospermia patients receiving two tablets of sperigen daily manufactured by BioArvand Pharmed Pharmaceutical Company and two tablets of coenzyme Q
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Infertile couple with a male cause identified by the symptoms of idiopathic oligoasthenoteratospermia. Definitive diagnosis of oligoasthenoteratospermia based on sperm count of less than 15 million per cc of semen, Sperm movement less than 32, Normal sperm morphology less than 4%. Men age range 18-50 years old Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm.
Exclusion criteria
Exclusion criteria: Patients with a history of reproductive system problems, including: undescended testicles, Klinefelter syndrome, hypogonadism, varicocele, cryptorchidism, and azoospermia and infection in reproductive tract and reproductive system Patients with a history of inflammation and injury to the testicles that caused infertility Patients with underlying disorder including: diabetes mellitus, hypothalamus and pituitary diseases and with thyroid gland problems, hypervitaminosis D and A, kidney stones and uncontrolled hypertension History of allergy to the components of medicines: sperigen tablets and Q10 supplement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm functional parameters (morphology, movement, number). Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: Para-clinical.;Permeability of sperm mitochondrial membrane. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: Measuring the mitochondrial membrane potential (MMP). | — |
Secondary
| Measure | Time frame |
|---|---|
| Breakage rate of sperm nuclear DNA. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: SDFA kit.;Reactive oxygen species (ROS) level of semen liquid. Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: ROS kit.;Expression level of apoptosis genes: survivin (anti-apoptotic gene) and caspase 3 (apoptotic gene). Timepoint: Before intervention and during the study and the endpoint the study. Method of measurement: RT-PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahmoud Omidi
Bandare-abbas University of Medical Sciences
Outcome results
None listed